

## Santhera Share Capital

The share capital and potential dilution as at June 30, 2023 and on a proforma basis, reflecting the sale of treasury shares to Catalyst and the repayment of exchangeable notes to Highbridge Capital is summarized below.

<i>Number of shares in thousands</i> <sup>1</sup>	As of June 30, 2023	Effect of transactions <sup>2,3</sup>	Pro forma post transactions
<b>Share capital</b>			
Issued shares	12,559		12,559
Treasury shares	(3,410)	1,415 <sup>2</sup>	(1,995)
<b>Issued shares net of treasury</b>	<b>9,149</b>		<b>10,563</b>
<b>Earmarked for conversion</b>			
	Conversion price (CHF)		
Exchangeable Notes		(3,907) <sup>3</sup>	0
Convertible Bond 21/24 - listed	30.03	-	452
Convertible Bond 21/24 - private	5.00-10.00	-	1,677
Warrants	5.00-20.00	-	1,403
Options	0.00-1,126.00	-	1,399
<b>Shares earmarked</b>	<b>8,838</b>	<b>(3,907)</b>	<b>4,931</b>
<b>Potentially fully diluted number of shares, net of treasury</b>			
	<b>17,986</b>	<b>(2,492)</b>	<b>15,494</b>

<sup>1</sup> Share numbers are adjusted to take account of reverse share split approved by the AGM of June 27, 2023, and completed on July 5, 2023

<sup>2</sup> Sale of treasury shares to Catalyst Pharmaceuticals

<sup>3</sup> Repayment of exchangeable notes to Highbridge Capital